Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$106.17
+0.5%
$112.00
$89.67
$121.64
$184.70B0.765.55 million shs6.56 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$76.32
+0.7%
$68.58
$60.47
$76.80
$236.63B0.476.36 million shs6.66 million shs
Novartis AG stock logo
NVS
Novartis
$99.07
+1.4%
$97.16
$92.19
$108.78
$202.50B0.531.55 million shs1.16 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.78
-1.4%
$26.92
$25.20
$40.37
$157.28B0.6343.59 million shs65.40 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.51%+0.22%-4.52%-6.30%-4.27%
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.74%+0.58%+13.15%+14.68%+1.31%
Novartis AG stock logo
NVS
Novartis
+1.36%+2.00%+3.42%-4.25%-5.57%
Pfizer Inc. stock logo
PFE
Pfizer
-1.40%+8.45%+4.18%+0.78%-28.17%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9884 of 5 stars
3.35.04.24.52.22.52.5
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.121 of 5 stars
1.33.01.70.03.20.03.1
Novartis AG stock logo
NVS
Novartis
3.1254 of 5 stars
2.05.02.50.02.60.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9909 of 5 stars
4.23.04.24.83.71.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.67
Moderate Buy$121.5014.44% Upside
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.57
Moderate Buy$81.006.13% Upside
Novartis AG stock logo
NVS
Novartis
2.00
Hold$115.0016.08% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.0029.61% Upside

Current Analyst Ratings

Latest NVS, ABT, AZN, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024
Pfizer Inc. stock logo
PFE
Pfizer
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/26/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/24/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$124.00
4/24/2024
Novartis AG stock logo
NVS
Novartis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
4/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$141.00 ➝ $140.00
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/16/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00
4/3/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $128.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.60$6.38 per share16.65$22.36 per share4.75
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B5.17$5.39 per share14.15$12.63 per share6.04
Novartis AG stock logo
NVS
Novartis
$45.44B4.46$11.32 per share8.75$22.87 per share4.33
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.69$2.97 per share9.34$15.81 per share1.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2133.0720.742.5513.96%20.18%10.60%7/18/2024 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$2.0437.4116.381.3913.30%30.42%11.62%7/26/2024 (Estimated)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.4113.3712.171.5631.33%32.15%13.59%7/16/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.101.17-0.56%8.58%3.70%8/6/2024 (Estimated)

Latest NVS, ABT, AZN, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    
2/8/202412/31/2023
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.74$0.73-$0.01$1.15$12.07 billion$12.02 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.07%+12.31%68.54%53 Years
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.53%+1.18%94.61%1 Years
Novartis AG stock logo
NVS
Novartis
$2.432.45%+4.26%32.79%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.05%+2.57%N/A 15 Years

Latest NVS, ABT, AZN, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
2/8/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Semi-Annual$0.96502.3%2/22/20242/23/20243/25/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.11
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.73
0.89
0.70
Novartis AG stock logo
NVS
Novartis
0.43
0.90
0.71
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.47%
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.04 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

NVS, ABT, AZN, and PFE Headlines

SourceHeadline
Pfizer reports young patient death in Duchenne gene therapy trialPfizer reports young patient death in Duchenne gene therapy trial
newshub.co.nz - May 8 at 3:32 AM
UPDATE 2-Pfizer reports patient death in Duchenne gene therapy studyUPDATE 2-Pfizer reports patient death in Duchenne gene therapy study
finance.yahoo.com - May 7 at 10:31 PM
Pfizer reports patient death in Duchenne gene therapy studyPfizer reports patient death in Duchenne gene therapy study
reuters.com - May 7 at 5:04 PM
Pfizer (NYSE:PFE) Trading Up 0.5%Pfizer (NYSE:PFE) Trading Up 0.5%
marketbeat.com - May 7 at 3:52 PM
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareBiotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
investorplace.com - May 7 at 2:04 PM
Is Pfizer Stock Fully Valued At $28?Is Pfizer Stock Fully Valued At $28?
forbes.com - May 7 at 12:30 PM
Pfizer First Quarter 2024 Earnings: Beats ExpectationsPfizer First Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - May 7 at 12:30 PM
Pfizer: Solid Earnings, But Were Not Out Of The Woods YetPfizer: Solid Earnings, But We're Not Out Of The Woods Yet
seekingalpha.com - May 7 at 4:32 AM
Welch & Forbes LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)Welch & Forbes LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 7 at 12:17 AM
Pfizer (NYSE:PFE) Stock Price Up 0.8%Pfizer (NYSE:PFE) Stock Price Up 0.8%
marketbeat.com - May 6 at 7:33 PM
Andrew Baum To Oversee Pfizers Innovation, Portfolio StrategyAndrew Baum To Oversee Pfizer's Innovation, Portfolio Strategy
markets.businessinsider.com - May 6 at 7:16 PM
Pfizer: Ignore The Dead Cat BouncePfizer: Ignore The Dead Cat Bounce
seekingalpha.com - May 6 at 7:16 PM
Pfizer Is Adding a Wall Street Analyst to Its C-Suite. What He Thinks the Company Needs to Do.Pfizer Is Adding a Wall Street Analyst to Its C-Suite. What He Thinks the Company Needs to Do.
finance.yahoo.com - May 6 at 7:16 PM
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ YieldsMaximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
investorplace.com - May 6 at 2:22 PM
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to KnowInvestors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
zacks.com - May 6 at 10:01 AM
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings ReportPfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
marketbeat.com - May 6 at 8:58 AM
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of yearUPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year
finance.yahoo.com - May 6 at 7:38 AM
Pfizer Announces New Chief Strategy and Innovation OfficerPfizer Announces New Chief Strategy and Innovation Officer
businesswire.com - May 6 at 6:45 AM
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings ReportPfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
marketbeat.com - May 6 at 6:10 AM
Revive Your Portfolio: 3 Undervalued Stocks Poised for GrowthRevive Your Portfolio: 3 Undervalued Stocks Poised for Growth
investorplace.com - May 6 at 6:00 AM
Pfizer Inc. Expected to Earn FY2024 Earnings of $2.15 Per Share (NYSE:PFE)Pfizer Inc. Expected to Earn FY2024 Earnings of $2.15 Per Share (NYSE:PFE)
americanbankingnews.com - May 6 at 3:16 AM
Pfizer Inc. (NYSE:PFE) to Post Q2 2024 Earnings of $0.48 Per Share, Leerink Partnrs ForecastsPfizer Inc. (NYSE:PFE) to Post Q2 2024 Earnings of $0.48 Per Share, Leerink Partnrs Forecasts
americanbankingnews.com - May 6 at 2:44 AM
Pfizer Inc. (NYSE:PFE) Shares Purchased by Metis Global Partners LLCPfizer Inc. (NYSE:PFE) Shares Purchased by Metis Global Partners LLC
marketbeat.com - May 6 at 12:35 AM
3 No-Brainer Stocks to Buy in May3 No-Brainer Stocks to Buy in May
fool.com - May 5 at 6:55 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Novartis logo

Novartis

NYSE:NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.